Literature DB >> 23245877

Immunohistochemically defined subtypes and outcome of apocrine breast cancer.

Silvia Dellapasqua1, Patrick Maisonneuve, Giuseppe Viale, Giancarlo Pruneri, Giovanni Mazzarol, Raffaella Ghisini, Manuelita Mazza, Monica Iorfida, Nicole Rotmensz, Paolo Veronesi, Alberto Luini, Aron Goldhirsch, Marco Colleoni.   

Abstract

BACKGROUND: Conflicting data are available in the literature on the outcome of invasive apocrine carcinoma (IAC), possibly related to a heterogeneous classification of these tumors. PATIENTS AND METHODS: A series of 6899 consecutive patients with invasive ductal carcinoma (IDC) not otherwise specified and 72 patients with immunohistochemically defined IAC who received surgery at the European Institute of Oncology between 1997 and 2005 were included. We then explored patterns of recurrence of IAC according to 2 immunohistochemically defined tumor subtypes: pure apocrine carcinoma (estrogen [ER] and progesterone [PgR] receptor negative, and AR positive) and apocrine-like carcinoma (ER or PgR positive and AR negative).
RESULTS: The diagnosis of pure apocrine carcinoma was correlated with a worse outcome in terms of DFS (hazard ratio [HR] 1.7; 95% confidence interval [CI], 1.01-2.86; P = .0010) if compared with IDC, whereas IDC and apocrine-like breast cancers showed a similar outcome in terms of DFS and overall survival. Patients with pure apocrine carcinoma had an increased risk in contralateral breast cancer (HR, 4.12; 95% CI, 1.22-14; P = .02).
CONCLUSION: Pure apocrine carcinoma represents a distinct subtype of breast cancer with a significantly worse DFS as compared with IDC. AR determination might have an important prognostic implication in IAC. Moreover, AR-targeted therapy should be further explored within these tumors.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23245877     DOI: 10.1016/j.clbc.2012.11.004

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  13 in total

1.  High level PHGDH expression in breast is predominantly associated with keratin 5-positive cell lineage independently of malignancy.

Authors:  Irina Gromova; Pavel Gromov; Naoko Honma; Sudha Kumar; David Rimm; Maj-Lis Møller Talman; Vera Timmermans Wielenga; José M A Moreira
Journal:  Mol Oncol       Date:  2015-05-14       Impact factor: 6.603

2.  Tumor-infiltrating lymphocytes status, programmed death-ligand 1 expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses.

Authors:  Xuexue Xiao; Su Jin; Geling Zhangyang; Shiwei Xiao; Fang Na; Junqiu Yue
Journal:  Gland Surg       Date:  2022-06

3.  Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.

Authors:  Maria Vittoria Dieci; Enrico Orvieto; Massimo Dominici; PierFranco Conte; Valentina Guarneri
Journal:  Oncologist       Date:  2014-06-26

4.  Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas.

Authors:  Xiangjie Sun; Ke Zuo; Qianlan Yao; Shuling Zhou; Ruohong Shui; Xiaoli Xu; Rui Bi; Baohua Yu; Yufan Cheng; Xiaoyu Tu; Hongfen Lu; Wentao Yang
Journal:  Mod Pathol       Date:  2020-06-05       Impact factor: 7.842

5.  FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast.

Authors:  Pavel Gromov; Jaime A Espinoza; Maj-Lis Talman; Naoko Honma; Niels Kroman; Vera Timmermans Wielenga; José M A Moreira; Irina Gromova
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

6.  Expression of high affinity folate receptor in breast cancer brain metastasis.

Authors:  José Pablo Leone; Rohit Bhargava; Brian K Theisen; Ronald L Hamilton; Adrian V Lee; Adam M Brufsky
Journal:  Oncotarget       Date:  2015-10-06

7.  Dose invasive apocrine adenocarcinoma has worse prognosis than invasive ductal carcinoma of breast: evidence from SEER database.

Authors:  Ning Zhang; Hanwen Zhang; Tong Chen; Qifeng Yang
Journal:  Oncotarget       Date:  2017-04-11

Review 8.  Triple negative breast cancer: special histological types and emerging therapeutic methods.

Authors:  Lu Cao; Yun Niu
Journal:  Cancer Biol Med       Date:  2020-05-15       Impact factor: 4.248

9.  Neoadjuvant targeted therapy for apocrine carcinoma of the breast: A case report.

Authors:  Ping Yang; Shu-Jia Peng; Yan-Ming Dong; Lin Yang; Zhen-Yu Yang; Xi-E Hu; Guo-Qiang Bao
Journal:  World J Clin Cases       Date:  2020-12-06       Impact factor: 1.337

10.  Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.

Authors:  Emilia Montagna; Giuseppe Cancello; Eleonora Pagan; Vincenzo Bagnardi; Elisabetta Munzone; Silvia Dellapasqua; Giuseppe Viale; Giovanni Mazzarol; Paolo Veronesi; Viviana Galimberti; Giorgia Santomauro; Marco Colleoni
Journal:  Breast       Date:  2020-07-24       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.